# TB-500 Research: Actin Binding, Cardiac, Wound, Stroke and Safety Data > TB-500 research, tile by tile: the thymosin beta-4 actin-sequestration structure, the wound and cardiac results, the non-monotonic stroke dose-response, and the tumor-angiogenesis safety signal — each cited and species-flagged. Each result on its own tile, captioned for species — and flagged where the data are for full-length thymosin beta-4 rather than the TB-500 heptapeptide. ## The mechanism: 1:1 actin sequestration TB-500 research begins at the cytoskeleton. X-ray crystallography of a gelsolin-domain-1–thymosin beta-4 hybrid bound to actin, resolved at 2 angstroms, established that thymosin beta-4 forms a 1:1 complex with globular (G-) actin and sequesters the monomer by capping both ends, preventing polymerization [1]. The WH2 actin-interacting motif — the LKKTETQ segment carried by TB-500 — underlies this binding. That single mechanism organizes everything downstream. By holding a buffered reserve of unpolymerized actin, the peptide influences how readily cells remodel their cytoskeleton, which in turn shapes migration, motility, and the recruitment of repair cells. The structural result is for the parent protein; the fragment carries the binding motif but its independent activity at research doses is unproven [13]. ## Thymosin Beta-4: The Parent Protein Thymosin beta-4 is a ubiquitous 43-amino-acid peptide (gene TMSB4X, ~4,963 Da) that is the body's principal G-actin-sequestering molecule, released by platelets and macrophages after injury [5]. A 2012 review consolidated its profile: it binds actin and promotes cell mobilization and migration, decreases myofibroblast number to reduce scar formation, limits apoptosis and inflammation, and promotes angiogenesis — the rationale that took the protein into clinical trials for dermal wounds, corneal injury, and heart and CNS repair [5]. This is why the parent-protein distinction matters so much for TB-500. "Thymosin beta-4" was characterized in 2021 as a human exerkine and growth factor — a signaling factor released with exercise — which is the contemporary framing behind the athletic-recovery interest in the fragment [15]. But the exerkine, the wound data, and the cardiac data are all the full-length protein. The 7-mer inherits the name and the marketing, not necessarily the biology. ## Cardiac, wound, and angiogenesis findings In mice, thymosin beta-4 formed a functional complex with PINCH and integrin-linked kinase (ILK), activating the survival kinase Akt; after coronary artery ligation it enhanced early myocyte survival and improved cardiac function [2]. In a rat full-thickness wound model, topical or intraperitoneal thymosin beta-4 increased re-epithelialization by 42% at 4 days and up to 61% at 7 days versus saline, raised wound contraction by at least 11% by day 7, and increased collagen deposition and angiogenesis; as little as 10 pg stimulated keratinocyte migration two- to three-fold [3]. The angiogenic route is molecular: thymosin beta-4 induces vascular endothelial growth factor (VEGF) in a hypoxia-inducible factor (HIF)-1α-dependent manner [10], and promotes matrix metalloproteinase expression during wound repair to support extracellular-matrix remodeling [11]. Systemic dosing of thymosin beta-4 after ischemia was also cardioprotective in a rodent model [13]. Each of these used the full-length protein. ### Does TB-500 affect the heart? In mice, thymosin beta-4 activated the PINCH-ILK-Akt survival pathway and improved cardiac function after coronary artery ligation [2]. A counterweight: a porcine ischemia-reperfusion study found no attenuation of injury, which tempers the cardioprotection narrative. Human cardiac efficacy of the fragment is not established. ### Does TB-500 promote angiogenesis and is that a safety concern? Thymosin beta-4 induces VEGF in a HIF-1α-dependent manner and promotes endothelial migration [10]. This pro-angiogenic activity aids tissue repair, but it is also the basis of the tumor-angiogenesis safety signal discussed below — the same property cuts both ways. ## Neurological and anti-inflammatory data In male Wistar rats with embolic middle cerebral artery occlusion, intraperitoneal thymosin beta-4 (2, 12, or 18 mg/kg starting 24 hours post-stroke, then every 3 days for four more doses) improved neurological function at 2 and 12 mg/kg — significant from day 14 through day 56 — but 18 mg/kg gave no significant benefit, and the authors modeled an optimal dose near 3.75 mg/kg [4]. The dose-response is non-monotonic: more is not better. ### Does TB-500 have neuroprotective effects on the brain? In a rat embolic-stroke dose-response study, intraperitoneal thymosin beta-4 improved neurological function at 2 and 12 mg/kg but not at 18 mg/kg, with a modeled optimal dose around 3.75 mg/kg [4]. The benefit was non-monotonic, which directly undercuts community "loading" rationales. ### Does TB-500 reduce inflammation? Thymosin beta-4 suppressed corneal NF-κB as a potential anti-inflammatory pathway in the eye [12], and in vitro work has tied the protein to reduced inflammatory signaling. This is a mechanistic basis reported for the full-length protein, not a demonstrated clinical effect of the fragment. ### Does TB-500 increase hair growth? Hair-follicle bulge stem cells are a documented target of thymosin beta-4 in rodent models, where nanomolar concentrations stimulate their migration and differentiation [5]. This is a parent-protein finding and is not established for the TB-500 fragment in humans. ## TB-500 Side Effects and Safety Signals in the Literature The principal documented concern is not an acute toxicity but a mechanistic one. Thymosin beta-4 is overexpressed in several cancers — including pancreatic and colorectal — and is implicated in metastasis and tumor angiogenesis [13]. The same pro-migratory, pro-angiogenic properties that aid repair could, in principle, support tumor progression. That is the central safety consideration in the literature, and it follows directly from the mechanism rather than from an adverse-event report. ### Does TB-500 cause cancer or promote tumor growth? Thymosin beta-4 is overexpressed in several cancers and implicated in metastasis and tumor angiogenesis [13]. The pro-migratory, pro-angiogenic properties that aid repair could theoretically support tumor progression — a key safety consideration rather than a demonstrated outcome in humans. ### What are the side effects of TB-500? Human safety data for the fragment are scarce. The principal documented concern is the tumor and angiogenesis signal associated with thymosin beta-4 [13], alongside the unverified identity, purity, and sequence of research-grade material in an unregulated supply [13]. A 2026 Sports Medicine review notes the potential for serious harm and the scarcity of rigorous human data [14]. The honest counter-evidence belongs here too. In dystrophin-deficient (mdx) mice given 150 µg thymosin beta-4 intraperitoneally twice weekly for 6 months, the number of regenerating skeletal-muscle fibers rose significantly — but there was no improvement in muscle strength or systolic cardiac function, and skeletal and cardiac fibrosis remained elevated [9]. A positive histological marker did not translate into a functional gain. ## TB-500 compared with other repair peptides ### What is the difference between TB-500 and BPC-157? Both are research peptides studied for tissue repair, but they are structurally unrelated. TB-500 is the Ac-LKKTETQ actin-binding fragment of thymosin beta-4 [5]; BPC-157 is a distinct gastric-derived pentadecapeptide with no actin-sequestration mechanism. A 2026 Sports Medicine review lists both among unapproved musculoskeletal peptides [14]. ### How does TB-500 compare to other peptides for recovery and healing? A 2026 Sports Medicine review concluded that many unapproved repair peptides show favorable tissue-repair outcomes in animal models, but that rigorous human safety data are scarce, the potential for serious harm exists, and such compounds operate largely outside regulatory oversight [14]. TB-500 sits squarely in that description. ### Are there any human clinical trials on TB-500? There are no completed controlled clinical trials of the TB-500 heptapeptide for any indication [13]. Human data exist only for full-length thymosin beta-4: a randomized, placebo-controlled Phase 1 intravenous safety and pharmacokinetics study in healthy volunteers [6], and topical ophthalmic thymosin beta-4 (RGN-259) dry-eye trials. Efficacy of the 7-mer in humans is unproven. --- A bento board of the TB-500 record — each finding tiled and cited, every full-length-versus-fragment caveat flagged in the corner, with no clinic behind the board and nothing here dispensed or sold.